Profound Medical Corp (PROF) Stock Price, Quote & News

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices

Sector: Healthcare

Phone: 647 476 1350

Fax: 647 847 3739

Website: www.profoundmedical.com

Address:

2400 Skymark Avenue, Unit 6, Mississauga, Canada

QES Nov. 28 at 3:03 PM

$PROF https://finance.yahoo.com/news/profound-medical-launch-ai-powered-124500774.html This new BPH module is yet another major selling point for the TULSA Pro system. It comes less than 6 months after the first commercial BPH procedure. "On the company’s own math, BPH and hybrid BPH/cancer patients would expand the eligible pool by about 2× relative to the prostate-cancer-focused base, taking total from 1× to about 3×, i.e., BPH roughly doubles the market on top of what cancer alone provides. That does not automatically translate to revenue tripling (penetration, ASPs, and mix matter), but from an addressable-procedure standpoint, BPH is positioned by management as the main lever to move from a ~200k-case world to a ~600k-case world."

1 · Reply

johntarlick Nov. 21 at 1:54 PM

$PROF some interesting patterns in the institutional holdings for Q3. Longtime holders Letko and Timelo took substantial reductions of about 20%, even as RayJames has virtually exited their position altogether. On the plus side, Royce increased their position. Gagnon's stayed on the sidelines despite the very attractive prices recently. RayJames had been an inveterate booster of this stock for years dating back to former analyst Rahul Sarugaser, and just two months ago issued an "OUTPERFORM" targeting $11.00. What happened? Am I reading fintel.io wrong?

0 · Reply

johntarlick Nov. 21 at 1:32 PM

$PROF i had thought this stock was on the move at last, following what seemed like a great earnings call, and proving me wrong when i asserted below they'd never get 7.50 on a share offering this year. Then we promptly gave up 15%?? what happened.

0 · Reply

BioTuesdays Nov. 19 at 2:09 AM

$PROF has announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA Procedures™ performed independently by a urologist, without radiologist involvement. This landmark establishes a new model for delivering MRI-guided prostate therapy https://biotuesdays.com/2025/11/18/profound-celebrates-the-hong-centers-200th-independent-tulsa-procedure-dr-mark-hong-sees-tulsa-ultimately-replacing-radical-prostatectomy-as-a-first-line-option-for-prostate-cancer/

0 · Reply

healthcareguru Nov. 14 at 4:20 PM

$PROF New BANKRUPTCY risk filed…you were warned. Enjoy the epic dilution which is the VERY NEXT CATALYST. Going <$3 quickly… 🐺👎 $IHI $IWM $XLV $XBI

3 · Reply

jiggs10 Nov. 14 at 3:59 PM

$PROF. Prof and $EDAP should just merge to put up better numbers together n complete more with $ISRG ...

2 · Reply

QES Nov. 14 at 3:00 PM

$PROF healthcareguru ... most buyers of PROF are not retail, but institutions. They don't read these posts here. And it looks like they, and their AI algorithms, like what they saw in the Earnings. The company is finally selling systems, and the potential customer list is growing.

1 · Reply

healthcareguru Nov. 14 at 2:40 PM

$PROF morons - they just filed for 50% dilution…it’s imminent. 😂😂😂😂😂👎👎👎👎👎🐺🐺🐺🐺 $3 PT. https://www.sec.gov/Archives/edgar/data/1628808/000110465925111470/tm2529759d1_s3.htm

0 · Reply

QES Nov. 14 at 1:41 PM

$PROF I want to see sales, and these are impressive numbers. Minimum of five more coming online within the next two months, the list of interested parties is up, and international expansion underway. And Canada has only ONE system in place? Geez, that will be fixed too. Sooner or later, TULSA Pro will catch fire, as word spreads. No cutting, no blood. Not even an overnight hospital stay.... The more units installed, the easier it should be to sell the systems. Patience should pay nicely here.

0 · Reply

johntarlick Nov. 14 at 12:36 PM

$PROF oh and the sonalleve gambit was decidedly odd. They've been sitting on that technology for almost a decade, and done nothing with it. I'm satisfied with the first half of the answer given, that they had all their resources committed to prostate. But the second half of the answer is strange: they are suddenly interested in their own sonalleve technology, because histosonics went unicorn?? something about that sequence isn't convincing me that steady hands and clear long-term vision are guiding this ship. it's more like loose cannons in the c-suite reacting to each passing wave only as it is right underneath the ship.

1 · Reply

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

Nov 18, 2025, 4:15 PM EST - 15 days ago

Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

Nov 13, 2025, 10:11 PM EST - 20 days ago

Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript

PRN

Nov 13, 2025, 4:05 PM EST - 20 days ago

Profound Medical Reports Strong Third Quarter 2025 Financial Results

Nov 12, 2025, 8:30 AM EST - 21 days ago

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

Nov 11, 2025, 4:15 PM EST - 22 days ago

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

Oct 14, 2025, 8:30 AM EDT - 7 weeks ago

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

Oct 7, 2025, 7:45 AM EDT - 2 months ago

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Sep 23, 2025, 8:00 AM EDT - 2 months ago

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference

Aug 18, 2025, 7:01 PM EDT - 3 months ago

Profound Medical: Smokes Is Everywhere, Initiate At Sell

Aug 14, 2025, 9:24 PM EDT - 3 months ago

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

PRN

Aug 14, 2025, 4:05 PM EDT - 3 months ago

Profound Medical Announces Second Quarter 2025 Financial Results

Jul 24, 2025, 5:00 PM EDT - 4 months ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

May 14, 2025, 4:45 PM EDT - 7 months ago

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

May 9, 2025, 7:17 AM EDT - 7 months ago

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

Apr 30, 2025, 4:30 PM EDT - 7 months ago

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Apr 15, 2025, 7:45 AM EDT - 8 months ago

Profound Medical AUA 2025 Investor Event Agenda

Apr 8, 2025, 10:00 AM EDT - 8 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 8, 2025, 9:32 AM EDT - 8 months ago

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Apr 6, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Apr 4, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Apr 3, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 8 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Mar 31, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Mar 28, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Mar 26, 2025, 9:59 PM EDT - 9 months ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Mar 26, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Mar 25, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Mar 24, 2025, 1:00 PM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Mar 6, 2025, 8:35 PM EST - 9 months ago

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Feb 13, 2025, 5:00 PM EST - 10 months ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Jan 8, 2025, 7:30 AM EST - 11 months ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 6, 2025, 8:15 AM EST - 11 months ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 9:55 AM EST - 1 year ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Dec 6, 2024, 9:04 AM EST - 1 year ago

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Dec 5, 2024, 4:48 PM EST - 1 year ago

Profound Medical Announces Proposed Public Offering of Common Shares

Dec 2, 2024, 7:30 AM EST - 1 year ago

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Nov 26, 2024, 7:45 AM EST - 1 year ago

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Nov 10, 2024, 8:50 AM EST - 1 year ago

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 6:55 AM EST - 1 year ago

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

QES Nov. 28 at 3:03 PM

1 · Reply

johntarlick Nov. 21 at 1:54 PM

0 · Reply

johntarlick Nov. 21 at 1:32 PM

0 · Reply

BioTuesdays Nov. 19 at 2:09 AM

0 · Reply

healthcareguru Nov. 14 at 4:20 PM

$PROF New BANKRUPTCY risk filed…you were warned. Enjoy the epic dilution which is the VERY NEXT CATALYST. Going <$3 quickly… 🐺👎 $IHI $IWM $XLV $XBI

3 · Reply

jiggs10 Nov. 14 at 3:59 PM

$PROF. Prof and $EDAP should just merge to put up better numbers together n complete more with $ISRG ...

2 · Reply

QES Nov. 14 at 3:00 PM

1 · Reply

healthcareguru Nov. 14 at 2:40 PM

0 · Reply

QES Nov. 14 at 1:41 PM

0 · Reply

johntarlick Nov. 14 at 12:36 PM

1 · Reply

johntarlick Nov. 14 at 12:31 PM

$PROF making their guidance yes, and much of the news seems good. but i was expecting the cash burn to be down more substantially than that, what with the July 1 round of layoffs and what i had assumed was a desire to correct the poor optics. With the burn rate under control I had thought break-even was possible within one more year, but it seems more likely now to be two years. So that's two more rounds of dilution. The last one was eked out at 7.50, but i doubt they'll get anything close to that this year. Hang on for the ride!

0 · Reply

healthcareguru Nov. 14 at 1:11 AM

$PROF Official dilution announcement is hours to days away…FREEFALL daily until they rip the painful bandaid off, then 40%+ gap down. CASH INCINERATION => Bad Things Happen. 🐺👎 $XBI $IWM $QQQ $XLV

1 · Reply

healthcareguru Nov. 14 at 1:07 AM

$PROF >50% of mkt cap dilution authorization (S-3 registration statement) filed TONIGHT after they lied through their teeth on that bullshit call… <$3 incoming fast, suckers. 🤦‍♂️🤦‍♂️👎👎🐺🐺 $XLV $IHI $IWM $XBI https://www.sec.gov/Archives/edgar/data/1628808/000110465925111470/tm2529759d1_s3.htm

0 · Reply

BioTuesdays Nov. 13 at 10:16 PM

$PROF announced that total revenues for the third quarter of 2025 were $5.3 million, representing year-over-year revenue growth of 87%. The gross margin for the third quarter of 2025 was 74.3%, up 1,119 basis points year-over-year from 63.1% in the prior year period https://biotuesdays.com/2025/11/13/profound-releases-record-q3-2025-financial-results-says-its-happening/

0 · Reply

healthcareguru Nov. 13 at 10:05 PM

$PROF ZERO chance they can hit 2026 Street estimates…and he just sounded soft on 4Q25 too, which would imply a terrible exit rate. 👎

1 · Reply

healthcareguru Nov. 13 at 10:01 PM

$PROF NEWS FLASH: Whenever a company talks about how much $$ docs make on their procedure, it’s a RED FLAG!!!! Ticking time bomb until govt crackdown… 🤦‍♂️👎

1 · Reply

healthcareguru Nov. 13 at 9:59 PM

$PROF Wait wait wait…wtf!! Urologists are a competitive bunch and want to flex those juices?!?

0 · Reply

QES Nov. 13 at 9:53 PM

$PROF Q2=The Company’s TULSA-PRO® qualified sales pipeline is also growing, and now stands at 80 new systems being classified within one of the “Verify, Negotiate and Contracting” stages. Q3=sales pipeline is also growing and currently stands at 93 new systems being classified within one of the “Verify, Negotiate and Contracting” stages. - - - October 7, had 67 systems November 13, now 70 systems. - - - Cash raise will come. But sales are coming nicely. IMO, great long term outlook.

1 · Reply

healthcareguru Nov. 13 at 9:45 PM

$PROF $4 open? Yuck. 🤦‍♂️

1 · Reply

d_risk Nov. 13 at 9:43 PM

$PROF - Profound Medical Corp. Common Stock - 10Q - Updated Risk Factors PROF flags substantial doubt about its ability to continue as a going concern and warns that any unwaived debt default could severely impact operations, financials, and share price. #MedicalDevices #MarketVolatility #DebtDefault #GoingConcern #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/PROF/10-Q/2025-11-13

0 · Reply

healthcareguru Nov. 13 at 9:18 PM

$PROF based on current pathetic cash levels and insane burn rates, these guys need minimum 30-50% dilution just to stay around for another year. And they don’t get any bonus points for doing low margin OUS distributor deals…Just terrible. $3 PT. 🤦‍♂️

0 · Reply

healthcareguru Nov. 13 at 9:15 PM

$PROF this trash is cooked…new IPO and they already going bankrupt. 👎

0 · Reply

Market Cap	189.17M
Revenue (ttm)	10.68M
Net Income (ttm)	-27.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-260.49%
Debt to Equity Ratio	0.14

Volume	162,500
Avg Vol	82,046
Day's Range	N/A - N/A
Shares Out	30.19M
Stochastic %K	90%
Beta	0.57
Analysts	Strong Sell
Price Target	$12.31